多次输注体外扩增调节性T细胞促进CD163+髓系细胞及非淋巴清除非人灵长类肾移植存活
该研究在非淋巴清除非人灵长类肾移植模型中,评估自体体外扩增多克隆调节性T细胞(Treg)对移植肾存活的影响。五只动物接受递减他克莫司和CTLA4免疫球蛋白联合或不联合Treg输注。Treg输注将中位移植肾存活时间从35天显著延长至70天,并与循环HLA-DR+髓系细胞CD163表达及可溶性CD163水平显著升高相关。
要点
- Treg输注将中位移植肾存活时间从35天显著延长至70天。
- Treg输注与循环HLA-DR+髓系细胞CD163表达及可溶性CD163水平显著升高相关。
- Treg输注后移植肾浸润CD163+细胞增加,提示M2样髓系细胞增强。
核心结论
- 多次Treg输注与M2样髓系细胞增强相关,可能介导免疫调节、抗炎和移植物修复效应。
研究设计与样本
- 在临床相关非人灵长类模型中,五只动物接受递减他克莫司和CTLA4免疫球蛋白联合或不联合Treg输注。
- 外周血Tregs被分离并使用人工抗原提呈细胞扩增。
- Treg剂量在移植后第6、10、13、16、20、23、27和30天递增给予。
主要发现
- Treg输注将中位移植肾存活时间从35天显著延长至70天。
- 输注Tregs的Treg标志(Ki67和Bcl-2)表达在输注后减弱,但与循环天然Tregs相当。
- Treg输注未观察到循环供体反应性T细胞应答或总Treg百分比或移植肾浸润T细胞亚群的重大变化。
- Treg输注与循环HLA-DR+髓系细胞CD163表达显著增加及循环可溶性CD163水平升高相关。
- Treg输注后移植肾浸润CD163+细胞增加。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical verification of adoptively transferred regulatory T cell (Treg) efficacy in transplantation remains challenging. Here, we examined the influence of autologous ex vivo-expanded polyclonal Tregs on kidney graft survival in a clinically relevant non-human primate model. Peripheral blood Tregs were isolated and expanded using artificial antigen presenting cells. Immunosuppression was comprised of tapered tacrolimus and CTLA4 immunoglobulin, in five animals each without or with Treg infusions. Escalating Treg doses were administered 6, 10, 13, 16, 20, 23, 27 and 30 days after transplant. Infused Tregs were monitored for Treg signature, anti-apoptotic (Bcl-2) and proliferation (Ki67) marker expression. Treg infusions prolonged median graft survival time significantly from 35 to 70 days. Treg marker (Ki67 and Bcl-2) expression by infused Tregs diminished after their infusion but remained comparable to that of circulating native Tregs. No major changes in circulating donor-reactive T cell responses or total Treg percentages, or in graft-infiltrating T cell subsets were observed with Treg infusion. However, Treg infusion was associated with significant increases in CD163 expression by circulating HLA-DR+ myeloid cells and elevated levels of circulating soluble CD163. Further, graft-infiltrating CD163+ cells were increased with Treg infusion. Thus, multiple Treg infusions were associated with M2-like myeloid cell enhancement that may mediate immunomodulatory, anti-inflammatory and graft reparative effects.
引用
- Sasaki K, Kubo M, Wang YC, et al. Multiple infusions of ex vivo-expanded regulatory T cells promote CD163+ myeloid cells and kidney allograft survival in non-lymphodepleted non-human primates. Kidney Int. 2023. PMID: 37839695. doi:10.1016/j.kint.2023.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。